The mutation rate of the Omicron sublineage has led to baseline resistance against all
previously authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more …

COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic
management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 …

In 1918 many countries, but not Spain, were fighting World War I. Spanish press could report
about the diffusion and severity of a new infection without censorship for the first-time, so that …

Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for
prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the …

Background Long COVID, also known as post-acute sequelae of COVID-19 (PASC), is
characterized by persistent clinical symptoms following COVID-19. Objective To correlate …

Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …

Despite vaccination and antiviral therapies, immunocompromised individuals are at risk for
prolonged SARS-CoV-2 infection, but the immune defects that predispose to persistent …

The emergence and worldwide spread of SARS-CoV-2 during the COVID-19 pandemic
necessitated the adaptation and rapid deployment of viral WGS and analysis techniques that …

Summary Introduction Continued SARS-CoV-2 infection among immunocompromised
individuals is likely to play a role in generating genomic diversity and the emergence of …

Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …